MDGL Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Madrigal Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$317.09 |
| 52 Week High | US$368.29 |
| 52 Week Low | US$168.25 |
| Beta | -0.47 |
| 11 Month Change | 51.80% |
| 3 Month Change | 27.51% |
| 1 Year Change | 66.47% |
| 33 Year Change | 272.43% |
| 5 Year Change | 187.19% |
| Change since IPO | 3,024.01% |
Recent News & Updates
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion
Nov 03Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically
Nov 02
Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings
Oct 24Recent updates
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion
Nov 03Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically
Nov 02Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings
Oct 24Broker Revenue Forecasts For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Are Surging Higher
Aug 09While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market
Aug 08Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long
Jun 09Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
Apr 24Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge
Mar 15Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential
Feb 07Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Dec 20We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Aug 05Madrigal: Buy And Hoard Before Q4 Data Readout
Aug 04Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout
Jul 08Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate
May 11Madrigal: NASH Data In Q4 Is The Key
Apr 19We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Feb 24Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come
Jan 31Madrigal: Powerful Catalyst Approaching
Jan 09We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Nov 08We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Jul 26Shareholder Returns
| MDGL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.6% | -6.5% | -1.0% |
| 1Y | 66.5% | 14.6% | 30.3% |
Return vs Industry: MDGL exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: MDGL exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| MDGL volatility | |
|---|---|
| MDGL Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MDGL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MDGL's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 376 | Bill Sibold | www.madrigalpharma.com |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc. Fundamentals Summary
| MDGL fundamental statistics | |
|---|---|
| Market cap | US$6.85b |
| Earnings (TTM) | -US$518.67m |
| Revenue (TTM) | US$76.81m |
90.0x
P/S Ratio-13.3x
P/E RatioIs MDGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDGL income statement (TTM) | |
|---|---|
| Revenue | US$76.81m |
| Cost of Revenue | US$2.79m |
| Gross Profit | US$74.03m |
| Other Expenses | US$592.70m |
| Earnings | -US$518.67m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -23.78 |
| Gross Margin | 96.37% |
| Net Profit Margin | -675.24% |
| Debt/Equity Ratio | 15.1% |
How did MDGL perform over the long term?
See historical performance and comparison